Private equity firms are actively pursuing pathology assets as demand for precision diagnostics surges. Astorg, Cinven, Nordic Capital, Consonance, and Pike Street are among the firms targeting transactions in this space, according to PE Hub. The healthcare subsector is attracting investment as chronic diseases rise and data analytics capabilities advance.

Digital pathology technologies and lab services are seeing increased deal activity across multiple subsectors. The integration of AI and data analytics is driving investments toward faster diagnostics and improved workflows. This technological evolution is making pathology services more attractive to private equity investors seeking growth opportunities in healthcare.

The convergence of rising chronic disease prevalence and technological advancements is creating a perfect storm for investment in pathology services. As consumers demand better access to precision diagnostic services, private equity firms are positioning themselves to capitalize on this growing market segment.